Abstract
There is conflicting evidence regarding the effect of endothelin-1 (ET-1) on platelets. Some studies show that ET-1 activates platelets, others show platelet inhibition with ET-1 and some studies did not detect an effect of ET-1. These conflicting results may be due to complex interactions between platelet ETA and ETB receptors. ET-1 antagonism may emerge as an important therapeutic strategy in the management of several vascular disorders. However, to date the only prescribed ET-1 antagonist is bosentan for pulmonary arterial hypertension. Bosentan is a dual ET- 1 antagonist (i.e. it acts on both ETA and ETB receptors). Whether this action involves an effect on platelets remains to be established. In this review some of the studies describing the effect of ET-1 on human platelets are discussed. Vascular diseases where ET-1 is implicated are also considered.
Keywords: endothelin, platelet, bosentan, pulmonary hypertension, vascular disease
Current Vascular Pharmacology
Title: Endothelin-1 and Human Platelets
Volume: 3 Issue: 4
Author(s): I. Anita Jagroop, Stella S. Daskalopoulou and Dimitri P. Mikhailidis
Affiliation:
Keywords: endothelin, platelet, bosentan, pulmonary hypertension, vascular disease
Abstract: There is conflicting evidence regarding the effect of endothelin-1 (ET-1) on platelets. Some studies show that ET-1 activates platelets, others show platelet inhibition with ET-1 and some studies did not detect an effect of ET-1. These conflicting results may be due to complex interactions between platelet ETA and ETB receptors. ET-1 antagonism may emerge as an important therapeutic strategy in the management of several vascular disorders. However, to date the only prescribed ET-1 antagonist is bosentan for pulmonary arterial hypertension. Bosentan is a dual ET- 1 antagonist (i.e. it acts on both ETA and ETB receptors). Whether this action involves an effect on platelets remains to be established. In this review some of the studies describing the effect of ET-1 on human platelets are discussed. Vascular diseases where ET-1 is implicated are also considered.
Export Options
About this article
Cite this article as:
Jagroop Anita I., Daskalopoulou S. Stella and Mikhailidis P. Dimitri, Endothelin-1 and Human Platelets, Current Vascular Pharmacology 2005; 3 (4) . https://dx.doi.org/10.2174/157016105774329453
DOI https://dx.doi.org/10.2174/157016105774329453 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of microRNAs in Vascular Remodeling
Current Molecular Medicine ABC Transporters and Sterol Absorption
Current Drug Targets - Cardiovascular & Hematological Disorders Perioperative Considerations in Diabetic Patients
Current Diabetes Reviews Mechanisms of Medial Arterial Calcification in Diabetes
Current Pharmaceutical Design Experimental Models of Abdominal Aortic Aneurysms: An Overview
Current Pharmaceutical Design Nitric Oxide Therapies in Vascular Diseases
Current Pharmaceutical Design Transthyretin Cardiac Amyloidosis and Aortic Stenosis: Connection and Therapeutic Implications
Current Cardiology Reviews Chemosensitization of Prostate Cancer by Modulating Bcl-2 Family Proteins
Current Drug Targets Development of Scaffolds for Vascular Tissue Engineering: Biomaterial Mediated Neovascularization
Current Stem Cell Research & Therapy Atherosclerotic Plaque Stabilization - Potential Role for Immunomodulatory Therapy
Vascular Disease Prevention (Discontinued) Atherosclerotic Process in Seroreverter Children and Adolescents Exposed to Fetal Antiretroviral Therapy
Current HIV Research Intestinal MicrobiOMICS to Define Health and Disease in Human and Mice
Current Pharmaceutical Biotechnology Statins and Inflammation in Cardiovascular Disease
Current Pharmaceutical Design Statins Attenuate Fibrotic Manifestations of Cardiac Tissue Damage
Current Molecular Pharmacology Minimizing AED Adverse Effects: Improving Quality of Life in the Interictal State in Epilepsy Care
Current Neuropharmacology Ocular Inflammatory Diseases: Molecular Pathogenesis and Immunotherapy
Current Molecular Medicine Editorial: New Therapetic Approaches in the Management of Ischemia Reperfusion Injury and Cardiometabolic Diseases: Opportunities and Challenges
Current Drug Targets Short-term RR-Interval Power Spectral Analysis as a New Tool to Stratify the Risk of Sudden Death in Various Cardiovascular Conditions
Vascular Disease Prevention (Discontinued) Leukocyte Imaging of the Diabetic Foot
Current Pharmaceutical Design Proteomics Approaches to Understand Linkage Between Alzheimer’s Disease and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets